Related references
Note: Only part of the references are listed.Oncology phase I trial design and conduct: time for a change- MDICT Guidelines 2022
D. Araujo et al.
ANNALS OF ONCOLOGY (2023)
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
E. A. Rozeman et al.
NATURE MEDICINE (2021)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl et al.
LANCET (2019)
Rendering the 3+3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy
Lei Nie et al.
CLINICAL CANCER RESEARCH (2016)
TARGETED THERAPIES Redefining the primary objective of phase I oncology trials
Mark J. Ratain
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative Cancer Therapies (MDICT)
Christopher M. Booth et al.
EUROPEAN JOURNAL OF CANCER (2008)